TP53 and bladder transitional cell carcinoma: Importantly, a study conducted by Liu et al. (2023b) observed that BLCA tissues with co-mutations in TP53 and RB1 exhibited a greater presence of immune effectors, which showed a significant correlation with the response to immune checkpoint inhibitors (ICIs).